Cargando…
KRAS mutations in tumor tissue and plasma by different assays predict survival of patients with metastatic colorectal cancer
BACKGROUND: The optimal laboratory assay for detecting KRAS mutations in different biospecimens from patients with metastatic colorectal cancer (mCRC), and the clinical relevance of these gene alterations is still in question. We analyzed the prognostic–predictive relevance of KRAS status, determine...
Autores principales: | Xu, Jian-Ming, Liu, Xiao-Jing, Ge, Fei-Jiao, Lin, Li, Wang, Yan, Sharma, Manish R, Liu, Ze-Yuan, Tommasi, Stefania, Paradiso, Angelo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4272803/ https://www.ncbi.nlm.nih.gov/pubmed/25491325 http://dx.doi.org/10.1186/s13046-014-0104-7 |
Ejemplares similares
-
Impact of KRAS Mutation on Survival Outcome of Patients With Metastatic Colorectal Cancer in Jordan
por: Alkader, Mohammad S, et al.
Publicado: (2023) -
Mutational status of plasma exosomal KRAS predicts outcome in patients with metastatic colorectal cancer
por: Lucchetti, Donatella, et al.
Publicado: (2021) -
Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer
por: van de Haar, Joris, et al.
Publicado: (2023) -
KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer
por: Spindler, K G, et al.
Publicado: (2013) -
The Frequency of Specific KRAS Mutations, and Their Impact on Treatment Choice and Survival, in Patients With Metastatic Colorectal Cancer
por: Fernández Montes, Ana, et al.
Publicado: (2023)